|Application ||WB, IHC-P, E|
|Other Accession||B5DEH0, Q9QXD8, G5E5X0, NP_055055.1|
|Calculated MW||72190 Da|
|Antigen Region||438-467 aa|
|Other Names||LIM domain-containing protein 1, LIMD1|
|Target/Specificity||This LIMD1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 438-467 amino acids from the C-terminal region of human LIMD1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||LIMD1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Adapter or scaffold protein which participates in the assembly of numerous protein complexes and is involved in several cellular processes such as cell fate determination, cytoskeletal organization, repression of gene transcription, cell-cell adhesion, cell differentiation, proliferation and migration. Positively regulates microRNA (miRNA)-mediated gene silencing and is essential for P-body formation and integrity. Acts as a hypoxic regulator by bridging an association between the prolyl hydroxylases and VHL enabling efficient degradation of HIF1A. Acts as a transcriptional corepressor for SNAI1- and SNAI2/SLUG- dependent repression of E-cadherin transcription. Negatively regulates the Hippo signaling pathway and antagonizes phosphorylation of YAP1. Inhibits E2F-mediated transcription, and suppresses the expression of the majority of genes with E2F1- responsive elements. Regulates osteoblast development, function, differentiation and stress osteoclastogenesis. Enhances the ability of TRAF6 to activate adapter protein complex 1 (AP-1) and negatively regulates the canonical Wnt receptor signaling pathway in osteoblasts. May act as a tumor suppressor by inhibiting cell proliferation.|
|Cellular Location||Cytoplasm. Nucleus. Cytoplasm, P-body. Cell junction, adherens junction. Cell junction, focal adhesion Note=Shuttles between cytoplasm and nucleus but is localized predominantly to the cytoplasm. Found in the nucleus but not nucleoli. Colocalizes with VCL in the focal adhesions. Down- regulation and/or elimination of its expression from the nucleus of neoplastic cells correlates strongly with poor patient prognosis and aggressive forms of breast carcinoma. Conversely, strong nuclear localization correlates with low-tumor grade and better patient prognosis|
|Tissue Location||Expressed in normal and breast cancer tissues (at protein level). Ubiquitous.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
LIMD1 is a transcriptional regulator that inhibits E2F-mediated transcription, and suppresses the expression of the majority of genes with E2F1-responsive elements. May act as a tumor suppressor by inhibiting cell proliferation.
Ghosh, S., et al. Mol. Cancer 9, 58 (2010) :
Sharp, T.V., et al. Proc. Natl. Acad. Sci. U.S.A. 105(50):19932-19937(2008)
Spendlove, I., et al. Int. J. Cancer 123(10):2247-2253(2008)
Huggins, C.J., et al. Cancer Lett. 267(1):55-66(2008)
Huggins, C.J., et al. Cancer Genet. Cytogenet. 178(1):36-41(2007)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.